# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 31-40 of 2566 results.
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Status: Recruiting
Last Changed: Apr 16, 2019
First Received: Apr 16, 2019
Disease(s): Ovarian Cancer
Intervention(s): anti-MESO CAR-T cells
Locations: The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Writing About Experiences With Ovarian Cancer
Status: Completed
Last Changed: Oct 17, 2018
First Received: Nov 01, 2015
Disease(s): Ovarian Cancer
Intervention(s): Expressive Writing, Fact Writing (Control)
Locations: University of Maryland, College Park, College Park, Maryland, United States
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
Status: Completed
Last Changed: Jun 06, 2018
First Received: Apr 30, 2010
Disease(s): Ovarian Cancer
Intervention(s): ABT-888, pegylated liposomal doxorubicin, temozolomide
Locations: Site Reference ID/Investigator# 25028, Duarte, California, United States
Site Reference ID/Investigator# 25024, Encino, California, United States
Site Reference ID/Investigator# 25034, Los Angeles, California, United States
Site Reference ID/Investigator# 25037, Newport Beach, California, United States
Site Reference ID/Investigator# 25030, Chicago, Illinois, United States
... and 28 other locations.
Genetically Modified T Cells Against Ovarian Cancer
Status: Recruiting
Last Changed: Sep 19, 2019
First Received: Jun 14, 2017
Disease(s): Ovarian Cancer
Intervention(s): OC-IgT cells
Locations: Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
Status: Recruiting
Last Changed: Jan 21, 2020
First Received: Jan 24, 2019
Disease(s): Ovarian Cancer
Intervention(s): anti- MESO CAR-T cells, Fludarabine, Cyclophosphamide
Locations: Shanghai 6th People's Hospital, Shanghai, Shanghai, China
Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy
Status: Not yet recruiting
Last Changed: Feb 19, 2016
First Received: Feb 19, 2016
Disease(s): Ovarian Cancer
Intervention(s): Laparoscopy, Laparotomy
Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
Status: Active, not recruiting
Last Changed: Sep 10, 2019
First Received: Aug 22, 2018
Disease(s): Ovarian Cancer
Intervention(s): Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
Locations: Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States
Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States
Arizona Oncology Associates, PC - HAL, Scottsdale, Arizona, United States
Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
... and 67 other locations.
Imaging Study in Advanced Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jan 18, 2019
First Received: Jan 18, 2019
Disease(s): Ovarian Cancer
Intervention(s): Ultrasound, CT and WB-DWI/MRI
Locations: Gynecologic Oncology Center in Prague, Prague, Czechia
Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families
Status: Recruiting
Last Changed: May 17, 2019
First Received: Apr 18, 2017
Disease(s): Ovarian Cancer
Locations: University of Washington, Seattle, Washington, United States
p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer
Status: Completed
Last Changed: Feb 25, 2011
First Received: Feb 16, 2009
Disease(s): Ovarian Cancer
Intervention(s): P53-SLP vaccine, Cyclophosphamide
Locations: University Medical Centre Groningen, Groningen, Netherlands